Tonix

TNXP NASDAQ
0.5622
-0.0098
-1.71%
Closed 16:00 07/23 EDT
Open
0.5700
Prev Close
0.5720
High
0.5800
Low
0.5500
Volume
966.57K
Avg Vol (3M)
498.06K
52 Week High
42.10
52 Week Low
0.5500
% Turnover
6.30%
Market Cap
8.62M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Tonix TNXP stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
MORE >

Recently

Name
Price
%Change